Renaissance Technologies LLC Invests $1.02 Million in Immunic, Inc. $IMUX

Key Points

• Renaissance Technologies acquired 919,164 Immunic shares worth approximately $1.02 million, giving it a 6.75% stake. Institutional investors collectively own 51.82% of the company.
• Immunic reported a quarterly loss of $0.80 per share, beating analyst expectations of a $1.16 loss. The company’s stock opened at $16.06, near its 52-week high of $16.86.
• Analysts maintain a consensus “Buy” rating, with an average price target of $47.57, although ratings range from “Strong Buy” to “Sell.” Immunic is developing oral therapies, including its lead candidate vidofludimus calcium, for autoimmune diseases.

Renaissance Technologies LLC bought a new position in Immunic, Inc. (NASDAQ:IMUX - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm bought 919,164 shares of the company's stock, valued at approximately $1,020,000. Renaissance Technologies LLC owned approximately 6.75% of Immunic as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Qube Research & Technologies Ltd bought a new stake in Immunic during the 3rd quarter valued at $29,000. Two Sigma Investments LP acquired a new position in Immunic during the third quarter worth $52,000. Seven Fleet Capital Management LP bought a new position in shares of Immunic in the fourth quarter valued at $83,000. Virtu Financial LLC bought a new position in shares of Immunic in the third quarter valued at $99,000. Finally, XTX Topco Ltd acquired a new position in shares of Immunic during the fourth quarter valued at about $120,000. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Price Performance

IMUX opened at $16.06 on Friday. The company has a market capitalization of $219.06 million, a price-to-earnings ratio of -3.67 and a beta of 1.41. The firm's fifty day moving average price is $14.45 and its two-hundred day moving average price is $12.06. Immunic, Inc. has a 1 year low of $5.06 and a 1 year high of $16.86.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.36. As a group, equities analysts anticipate that Immunic, Inc. will post -4.49 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $22.00 target price (up from $5.00) on shares of Immunic in a research report on Thursday, April 30th. Roth Capital reaffirmed a "buy" rating and issued a $19.00 price target on shares of Immunic in a research report on Thursday, May 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunic in a research note on Friday, May 29th. LADENBURG THALM/SH SH raised Immunic to a "strong-buy" rating in a report on Wednesday, July 29th. Finally, B. Riley Financial lowered their price objective on Immunic from $40.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 22nd. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $47.57.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source